| Riska, Paul |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection |
|
|
| Active, not recruiting | 2 | 108 | Canada, US | CRS3123, Active Comparator | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) | Clostridioides Difficile Infection | 02/24 | 04/24 | | |
| Recruiting | 2 | 80 | US | REC-3964 | Recursion Pharmaceuticals Inc. | Recurrent Clostridioides Difficile Infection | 07/26 | 10/26 | | |
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia |
|
|
| Recruiting | 1/2 | 50 | US, RoW | AP-SA02, Placebo | Armata Pharmaceuticals, Inc., United States Department of Defense | Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus | 12/24 | 03/25 | | |
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus) |
|
|
| Completed | N/A | 1000 | Europe, US, RoW | | University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota | Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) | 08/24 | 08/24 | | |
| Rehman, Syed |
| Recruiting | 3 | 30 | Europe, US, RoW | Kedrion IVIG 10% | Kedrion S.p.A., Pharmaceutical company, KEDRION S.p.A, Kedrion S.p.A | Primary Immunodeficiency Disease | 04/26 | 10/26 | | |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection |
|
|
| Active, not recruiting | 2 | 108 | Canada, US | CRS3123, Active Comparator | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) | Clostridioides Difficile Infection | 02/24 | 04/24 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
NCT05347251: Effects of Cervicothoracic Mobility Program on Low Back Pain |
|
|
| Completed | N/A | 44 | RoW | Cervicothoracic mobility program, Conventional Treatment | Riphah International University | Back Pain | 12/22 | 01/23 | | |
NCT05392023: Effects of Scapular Stabilization Program in Patients Chronic Non-specific Neck Pain |
|
|
| Completed | N/A | 28 | RoW | Relaxation Exercises and Scapular Stabilization exercise program, Relaxation Exercises of cervico- scapular region | Riphah International University | Neck Pain | 12/22 | 01/23 | | |
NCT05392517: Effects of Self-mobilization Techniques in Chronic Thoracic Pain |
|
|
| Completed | N/A | 28 | RoW | self-mobilization technique along with conventional therapy, conventional therapy | Riphah International University | Thoracic | 12/22 | 01/23 | | |
NCT05395078: Effects of Thoracic Extension Versus Thoracic Stabilization Exercises in Patients With Maigne's Thoracic Pain |
|
|
| Completed | N/A | 32 | RoW | Conventional physical therapy treatment along with thoracic extension exercises, Conventional physical therapy treatment along with thoracic stabilization exercises | Riphah International University | Thoracic | 12/22 | 01/23 | | |
NCT05393973: Effects of Core Stability Versus Swiss Ball Exercise in Patients With Chronic Neck Pain |
|
|
| Completed | N/A | 42 | RoW | Core stability exercises along with conventional physical therapy, Swiss ball exercises along with the conventional physical therapy protocol | Riphah International University | Neck Pain | 12/22 | 01/23 | | |
NCT05393323: Effects of Cervical Distraction Versus Cervical Traction Techniques on Upper Cervical Pain |
|
|
| Completed | N/A | 42 | RoW | conventional physical therapy with distraction technique, conventional physical therapy with traction technique | Riphah International University | Neck Pain | 12/22 | 01/23 | | |
NCT05392036: Effects of Therapeutic Ultrasound Versus Shockwave Therapy in Medial Tibial Stress Syndrome in Recreational Runners |
|
|
| Completed | N/A | 54 | RoW | baseline physical therapy treatment along with shockwave therapy, baseline physical therapy treatment along with therapeutic ultrasound | Riphah International University | Medial Tibial Stress Syndrome | 12/22 | 01/23 | | |
NCT05393960: Effects of Lumbosacral Mobility Program on Tight Hamstrings |
|
|
| Completed | N/A | 78 | RoW | Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program., home based self strechings program only. | Riphah International University | Hamstring Tightness | 12/22 | 01/23 | | |
NCT05404646: Effects of Thoracic Mobility Versus Stretching Exercise Program in Patients of Cervical Radiculopathy |
|
|
| Completed | N/A | 44 | RoW | Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy, Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy | Riphah International University | Cervical Radiculopathy | 12/22 | 01/23 | | |
NCT04862910: Effects of Kinect-based Virtual Reality Training in Postmenopausal Women With Osteopenia |
|
|
| Completed | N/A | 52 | RoW | Kinect Based Virtual Reality Training, Control Group | Riphah International University | Postmenopausal Osteopenia | 06/23 | 06/23 | | |
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults |
|
|
| No Longer Available | N/A | | Europe, Canada, US | Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE), Angioedema | | | | |
NCT04841902: Effects of Life Style Intervention Manual in Pre Hypertensive Sedentary Population |
|
|
| Completed | N/A | 240 | RoW | Life Style Intervention Manual (With Exercise Under Supervision), General Advice, Life Style Intervention Manual (Home Based) | Riphah International University | Pre Hypertension | 11/23 | 12/23 | | |
NCT04949958: Effects of Exercise Based Manual in Sedentary Prediabetic Population |
|
|
| Completed | N/A | 108 | RoW | Exercise Based Manual (Supervised), Exercise Based Manual (Home Based), Control | Riphah International University | PreDiabetes | 10/23 | 11/23 | | |
NCT06049277: Mulligan Technique Versus McKenzie Extension Exercise Chronic Unilateral Radicular Low Back Pain |
|
|
| Completed | N/A | 32 | RoW | Mulligan techniques with manual traction, McKenzie extension exercises with manual traction | Riphah International University | Low Back Pain | 01/24 | 01/24 | | |
NCT06049251: ELDOA Technique Versus Lumbar SNAGS With Motor Control Exercises |
|
|
| Completed | N/A | 32 | RoW | ELDOA exercises, Lumbar SNAGS and motor control exercises | Riphah International University | Low Back Pain | 01/24 | 01/24 | | |
NCT06049264: Thoracic Spine Manual Traction With Mobilization Versus Manipulation |
|
|
| Completed | N/A | 34 | RoW | Thoracic spine manual traction with mobilization protocol., Thoracic manipulation protocol | Riphah International University | Thoracic | 01/24 | 01/24 | | |
NCT06049303: Paraffin Wax Bath With Joint Mobilization Technique in Post-traumatic Stiff Knee |
|
|
| Completed | N/A | 34 | RoW | Paraffin wax bath therapy and Maitland joint mobilization techniques, Maitland knee joint mobilization | Riphah International University | Knee Pain Chronic | 01/24 | 01/24 | | |
NCT06049316: Scapular Stabilization vs Functional Exercises on Chronic Neck Pain |
|
|
| Completed | N/A | 42 | RoW | Scapular stabilization exercises, Scapular functional exercises | Riphah International University | Neck Pain | 01/24 | 01/24 | | |
NCT06460870: Effect of Mojzisova Method on Pain, Menstrual Symptom and Insomnia in PD |
|
|
| Not yet recruiting | N/A | 26 | RoW | Mojzisova method, Stretching exercises | Riphah International University | Primary Dysmenorrhea | 09/24 | 09/24 | | |
NCT06751719: Proprioceptive, Calisthenic, and Kinesthetic Exercises for Chronic Low Back Pain |
|
|
| Recruiting | N/A | 38 | RoW | core stabilization exercises, heat therapy, proprioceptive exercises, calisthenic exercises, kinesthetic exercises | Riphah International University | Chronic Low Back Pain (CLBP) | 12/24 | 01/25 | | |
NCT06751732: Craniocervical Flexion Training for Reducing Migraine Headaches and Disability |
|
|
| Recruiting | N/A | 38 | RoW | Craniocervical Flexion Training (CCFT), Diaphragm Respiratory Training, Cervical Mobilization and Traction, Digital Compression on Muscle Trigger Points, Passive Stretching of Neck Muscles, Instruction on Postural Correction | Riphah International University | Episodic Migraine Headache | 12/24 | 01/25 | | |
| Windom, Hugh |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Moushey, Kelly |
NCT05248997: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis |
|
|
| Completed | 3 | 261 | US | rimegepant 75 mg ODT, Matching placebo | Pfizer, Biohaven Pharmaceutical Holding Company Ltd. | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | 03/24 | 04/24 | | |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
NCT05652907: Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) |
|
|
| Terminated | 2 | 2 | Canada, US | FSD201, Placebo | FSD Pharma, Inc. | Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic | 05/23 | 05/23 | | |
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection |
|
|
| Active, not recruiting | 2 | 108 | Canada, US | CRS3123, Active Comparator | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) | Clostridioides Difficile Infection | 02/24 | 04/24 | | |
| Devine, Kelly C |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Freeman, Kelly |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
| Arshad, Kehkashan |
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
|
|
| Recruiting | 3 | 190 | Japan, US, RoW | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 12/27 | 12/29 | | |
| Center, Call |
NCT06487364: Determination of the Minimal Detectable Change of the Parkinson's Disease Questionnaire-8 |
|
|
| Recruiting | N/A | 39 | RoW | Rehabilitation | Emre Şenocak | Parkinson Disease | 01/25 | 01/25 | | |
NCT06482502: Validity of the 6-Minute Pegboard and Ring Test in Parkinson's Patients |
|
|
| Recruiting | N/A | 34 | RoW | | Emre Şenocak | Parkinson Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 30 | RoW | Walking and Remembering Test | Emre Şenocak | Healthy Individuals | 01/25 | 01/25 | | |
| Talreja, Neetu |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
| Completed | 3 | 276 | Europe, Canada, Japan, US, RoW | Depemokimab (GSK3511294), Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nasal Polyps | 07/24 | 08/24 | | |
|
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT06603220: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria |
|
|
| Recruiting | 2 | 30 | US | Oral EVO756 | Evommune, Inc. | Chronic Inducible Urticaria | 03/25 | 04/25 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria |
|
|
| Completed | 1 | 33 | Europe, Canada, US | Oral EP262 | Escient Pharmaceuticals, Inc | Chronic Inducible Urticaria | 10/24 | 10/24 | | |
| Active, not recruiting | N/A | 718 | Europe, Canada, Japan, US | DUPIXENT®, dupilumab, REGN668, SAR231893 | Regeneron Pharmaceuticals, Sanofi | Asthma | 07/26 | 07/26 | | |
| Gil, Stephanie |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT06366750: A Study of Barzolvolimab in Patients with Prurigo Nodularis |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | barzolvolimab, Matching Placebo | Celldex Therapeutics | Prurigo Nodularis | 01/26 | 06/26 | | |
| Recruiting | 2 | 75 | Europe, Canada, US, RoW | barzolvolimab, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Eosinophilic Esophagitis | 03/25 | 08/25 | | |
| Rao, Jessica |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
MAC2v3, NCT03672630: Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease |
|
|
| Active, not recruiting | 2/3 | 474 | Canada, US | Azithromycin, Zithromax, Ethambutol, Myambutol, Rifampin, Rifadin | Kevin Winthrop, Patient-Centered Outcomes Research Institute, National Jewish Health, The University of Texas Health Science Center at Tyler, University Health Network, Toronto, New York University, Medical University of South Carolina, Mayo Clinic, Louisiana State University Health Sciences Center in New Orleans, University of California, San Diego, Stanford University, University of Kansas, Vancouver Clinic, University of California, San Francisco, University of Washington, Johns Hopkins University, University of Miami, Emory University, University of Iowa, University of North Carolina, Temple University, Loma Linda University, Columbia University, University of Wisconsin, Madison, Northwell Health, Kaiser Permanente Hawaii, James A. Haley Veterans Administration Hospital | Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection | 10/25 | 10/25 | | |
| Arthur, Andrea |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Husain, Faheem |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
| Recruiting | 3 | 915 | Europe, US, RoW | barzolvolimab, Matching placebo | Celldex Therapeutics | Chronic Spontaneous Urticaria | 10/26 | 04/27 | | |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Snedden, Madeline |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Tracy, Margaret |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
| Alfonso-Castillo, Glenda |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
| Pagulayan, Therese |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
